Back to NVAXView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
View Full LandscapeDrug Information
Target Indication
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Clinical Trial
NCT05249816Last updated: 10/17/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
XBB.1.5 Vaccine (Booster)Phase 3
COVID-19
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)Phase 3
COVID-19
NVX-CoV2705 VaccinePhase 3
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
SARS-CoV-2 rS/Matrix M1-AdjuvantPhase 3
SARS-CoV-2 Infection
NanoFluPhase 3
Influenza, Human
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts